Free cash flow margin has compressed sharply from 18.3% in Q4 2025 to just 5.5% in Q3 2026, with trailing ten-quarter buybacks of approximately $1.10B plus $78M in dividends outpacing $950.7M in cumulative operating cash flow and suggesting distributions are being supplemented by balance sheet reserves.
Chemed Corporation (CHE) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 363.15M | 388.27M | 417.5M | 330.3M | 309.89M | 308.6M | 489.29M | 301.25M | 287.14M | 162.5M | 135.39M | 171.5M | 110.28M | 150.85M | 131.77M | 174.34M | 86.01M | 160.83M | 112.08M | 99.58M | 98.59M | 80.01M | 94.16M | 22.59M | 29.52M | 34.36M | 51.84M | 27.5M | 20.8M | 33.4M | 35.8M |
| Operating CF Margin % | - | 15.35% | 17.17% | 14.59% | 14.51% | 14.43% | 23.53% | 15.54% | 16.11% | 9.75% | 8.59% | 11.11% | 7.57% | 10.67% | 9.21% | 12.86% | 6.72% | 13.51% | 9.76% | 9.05% | 9.68% | 8.74% | 12.81% | 8.66% | 11.64% | 10.17% | 14.59% | 6.06% | 5.46% | 9.77% | 11.89% |
| Operating CF Growth % | 79.44% | -7% | 26.4% | 6.59% | 0.42% | -36.93% | 62.42% | 4.91% | 76.71% | 20.02% | -21.05% | 55.51% | -26.89% | 14.48% | -24.42% | 102.7% | -46.52% | 43.49% | 12.55% | 1.01% | 23.22% | -15.02% | 316.8% | -23.48% | -14.08% | -33.71% | 88.5% | 32.21% | -37.72% | -6.7% | 90.43% |
| Net Income | 282.4M | 265.24M | 302M | 272.51M | 249.62M | 268.55M | 319.47M | 219.92M | 205.54M | 98.18M | 108.74M | 110.27M | 99.32M | 77.23M | 89.3M | 85.98M | 81.83M | 73.78M | 71.02M | 63.98M | 50.65M | 35.82M | 27.51M | -3.44M | -1.81M | -10.38M | 20.58M | 19.7M | 19.9M | 30.3M | 32.3M |
| Depreciation & Amortization | 67.59M | 64.84M | 63.05M | 60.87M | 59.17M | 59.05M | 56.58M | 45.2M | 38.86M | 35.63M | 34.64M | 33.5M | 33.07M | 32.39M | 30.52M | 29.5M | 29.04M | 27.9M | 27.5M | 26.57M | 23.8M | 23.34M | 20.18M | 12.81M | 14.36M | 24.12M | 23.45M | 20.1M | 17.3M | 15.2M | 18.8M |
| Stock-Based Compensation | 43.11M | 4.89M | 32.03M | 30.08M | 26.25M | 22.5M | 18.42M | 14.83M | 446K | 1.23M | 1.85M | 2.65M | 10.32M | 10.87M | 11.97M | 8.38M | 7.76M | 8.64M | 7.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 9.86M | -5.94M | -4.14M | -8.03M | -3.35M | -15.78M | 37.78M | -2.77M | 5.19M | 2.41M | -6.71M | 6.33M | 6.98M | -6.99M | -3.15M | 7.24M | -2.41M | 4.98M | 426K | 8.11M | 7.41M | -3.68M | 5M | -501K | 855K | -4.4M | 2.1M | 100K | 3.4M | -1.8M | -2.2M |
| Other Non-Cash Items | -2.41M | 35.54M | 16.42M | 14.18M | 11.67M | 1.07M | 12.61M | 16.48M | 7.33M | 29.05M | 13.71M | 9.06M | 16.31M | 19.06M | 15.71M | 16.57M | 18.02M | 20.84M | 15.06M | 18.83M | 22.74M | 15.25M | 12.08M | 15.16M | 20.75M | 28.43M | 1.1M | -2.4M | -10.4M | -15.1M | -8.5M |
| Working Capital Changes | -37.39M | 23.71M | 8.13M | -39.31M | -33.49M | -26.8M | 44.43M | 7.58M | 17.15M | -14.48M | -25.18M | 4.79M | -49.72M | 23.11M | -8.75M | 26.68M | -48.24M | 24.44M | -4.61M | -20.19M | -6.02M | 6.85M | 28.44M | 661K | -2.4M | 2.57M | 4.61M | -10M | -9.4M | 4.8M | 11.3M |
| Change in Receivables | -38.5M | -11.6M | 10.68M | -41.49M | -2.41M | -8.43M | 12.77M | -19.25M | -5.57M | 1.07M | -42.14M | 4.13M | -45.78M | -9.01M | -24.42M | 26.9M | -68.66M | 33.75M | -6.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 490K | 650K | 3.83M | -1.73M | -162K | -3.01M | 367K | -1.76M | -351K | 421K | 559K | -142K | 535K | 355K | 1.61M | -940K | -151K | 29K | -898K | -18K | -78K | 520K | -986K | 1.24M | 931K | 79K | -706K | -500K | -900K | -800K | 5.8M |
| Change in Payables | 3.31M | -5.19M | -9.28M | -9.35M | 15.34M | 9.83M | 19.1M | 28.42M | 8.94M | 12.89M | 891K | 476K | -25.82M | 40.34M | 4.95M | -1.4M | 13.81M | -8.11M | 5.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -163.37M | -59.34M | -143.91M | -60.64M | -59.4M | -57.76M | -61.56M | -190.76M | -105.22M | -67.61M | -39.86M | -50.32M | -43.53M | -31.35M | -40.68M | -34.11M | -35.7M | -22.84M | -28.63M | -31.72M | -27.73M | -41.74M | -353.21M | -7.78M | 41.02M | -19.09M | -31.32M | -32.2M | -25.2M | 126M | -84.4M |
| Capital Expenditures | -67.7M | -62.8M | -49.53M | -56.85M | -57.33M | -58.67M | -58.83M | -53.02M | -52.87M | -64.3M | -39.77M | -44.13M | -43.57M | -29.32M | -35.25M | -29.59M | -25.64M | -21.5M | -26.09M | -26.64M | -21.99M | -25.73M | -18.29M | -10.38M | -8.44M | -14.46M | -31M | -37.9M | -36.8M | -20.1M | -11M |
| CapEx % of Revenue | 2.54% | 2.48% | 2.04% | 2.51% | 2.69% | 2.74% | 2.83% | 2.74% | 2.97% | 3.86% | 2.52% | 2.86% | 2.99% | 2.07% | 2.47% | 2.18% | 2% | 1.81% | 2.27% | 2.42% | 2.16% | 2.81% | 2.49% | 3.98% | 3.33% | 4.28% | 8.73% | 8.36% | 9.65% | 5.88% | 3.65% |
| Acquisitions | -96.05M | -225K | -97.4M | -3.99M | -3.53M | 0 | -3.6M | -138.01M | -53.18M | -4.72M | 0 | -6.61M | -250K | -2.26M | -5.9M | -3.66M | -9.47M | -1.92M | -11.2M | -1.08M | -4.14M | -6.17M | -343.05M | -3.85M | -1.24M | -1.55M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 383K | 3.68M | 3.02M | 206K | 1.45M | 918K | 871K | 272K | 824K | 1.42M | -90K | 432K | 294K | 235K | 468K | -858K | -592K | 573K | 8.67M | -4M | -1.6M | -9.84M | 8.13M | -7.32M | 48.77M | -4.45M | -4.61M | -2M | -3.4M | 132M | -115.9M |
| Cash from Financing | -281.11M | -432.77M | -359.19M | -79.83M | -209.25M | -380.62M | -271.21M | -109.16M | -188.2M | -99.08M | -94.95M | -120.59M | -137.04M | -104.61M | -59.63M | -152.06M | -112.81M | -29.2M | -84.82M | -92.15M | -98.72M | -52.59M | 279.81M | -1.95M | -41.53M | -16.55M | -27.52M | -19.4M | -25.1M | -102.5M | 41.4M |
| Debt Issued (Net) | 245.87M | 10.97M | -15.75M | -81.75M | -99.38M | 196.88M | -90M | 800K | -13.53M | -850K | 16.76M | -57.43M | -29.74M | -11.41M | 1.92M | -826K | -581K | -19.98M | -11.37M | 18.27M | -81.99M | -49.84M | 198.06M | -1.02M | -35.09M | -11.38M | -16.96M | 7M | -2.9M | -82.7M | 63.8M |
| Equity Issued (Net) | -494.32M | -404.35M | -361.39M | -67.7M | -114.52M | -576.04M | -175.59M | -92.63M | -158.88M | -94.64M | -102.31M | -59.32M | -110.02M | -92.91M | -60.62M | -143.97M | -109.33M | -4.22M | -69.79M | -131.7M | -16.02M | 4.93M | 96.17M | 2.65M | -1.67M | -491K | -5.73M | -4.5M | -400K | 0 | -3.7M |
| Dividends Paid | -33.73M | -31.7M | -27.09M | -23.5M | -22.02M | -22.02M | -21.08M | -19.79M | -18.66M | -17.37M | -16.44M | -15.61M | -14.26M | -14.15M | -13.03M | -12.54M | -11.88M | -8.16M | -5.54M | -5.89M | -6.32M | -6.17M | -5.72M | -4.76M | -4.44M | -4.38M | -4.02M | -22.5M | -21.7M | -21M | -20.4M |
| Share Repurchases | -524.6M | -431.5M | -361.39M | -67.7M | -114.52M | -576.04M | -175.59M | -92.63M | -158.88M | -94.64M | -102.31M | -59.32M | -110.02M | -92.91M | -60.62M | -147.89M | -109.33M | -4.22M | -69.79M | -131.7M | -19.89M | -7.4M | -2.65M | -637K | -3.21M | -1.23M | -5.73M | -4.5M | -400K | 0 | -3.7M |
| Other Financing | 1.07M | -7.69M | 45.04M | 93.13M | 26.66M | 20.55M | 15.46M | 2.46M | 2.87M | 13.79M | 7.04M | 11.77M | 16.98M | 13.86M | 12.09M | 5.27M | 8.98M | 3.16M | 1.88M | 27.17M | 5.62M | -1.5M | -8.7M | 1.18M | -343K | -293K | -806K | 600K | -100K | 1.2M | 1.7M |
| Net Change in Cash | -81.33M | -103.83M | -85.61M | 189.83M | 41.23M | -129.78M | 156.52M | 1.33M | -6.29M | -4.19M | 583K | 595K | -70.29M | 14.89M | 31.45M | -11.84M | -62.5M | 108.79M | -1.36M | -24.29M | -27.86M | -14.31M | 20.76M | 12.86M | 29.01M | -1.27M | -7M | -24.1M | -29.5M | 56.9M | -7.2M |
| Free Cash Flow | 295.45M | 325.48M | 367.97M | 273.44M | 252.56M | 249.92M | 430.46M | 248.23M | 234.27M | 98.19M | 95.62M | 127.36M | 66.71M | 121.52M | 96.52M | 144.75M | 60.37M | 139.34M | 85.99M | 72.94M | 76.6M | 54.06M | 75.86M | 11.41M | 17.67M | 20.23M | 20.84M | -10.4M | -16M | 13.3M | 16.8M |
| FCF Margin % | 11.1% | 12.86% | 15.13% | 12.08% | 11.83% | 11.68% | 20.7% | 12.8% | 13.14% | 5.89% | 6.06% | 8.25% | 4.58% | 8.6% | 6.75% | 10.68% | 4.71% | 11.71% | 7.48% | 6.63% | 7.52% | 5.9% | 10.32% | 4.38% | 6.96% | 5.99% | 5.86% | -2.29% | -4.2% | 3.89% | 5.58% |
| FCF Growth % | -18.03% | -11.55% | 34.57% | 8.27% | 1.06% | -41.94% | 73.41% | 5.96% | 138.57% | 2.69% | -24.92% | 90.93% | -45.11% | 25.91% | -33.32% | 139.76% | -56.67% | 62.04% | 17.88% | -4.78% | 41.71% | -28.75% | 564.78% | -35.41% | -12.66% | -2.91% | 300.34% | 35% | -220.3% | -20.83% | 394.12% |
| FCF per Share | 22.49 | 22.61 | 24.23 | 17.99 | 16.73 | 15.68 | 26.25 | 15.02 | 13.94 | 5.87 | 5.70 | 7.31 | 3.74 | 6.54 | 4.99 | 6.91 | 2.62 | 6.13 | 3.68 | 2.91 | 2.87 | 2.06 | 3.08 | 0.57 | 0.89 | 1.04 | 1.05 | -0.49 | -0.79 | 0.66 | 0.85 |
| FCF Conversion (FCF/Net Income) | 1.05x | 1.46x | 1.38x | 1.21x | 1.24x | 1.15x | 1.53x | 1.37x | 1.40x | 1.66x | 1.25x | 1.56x | 1.11x | 1.95x | 1.48x | 2.03x | 1.05x | 2.18x | 1.58x | 1.56x | 1.95x | 2.23x | 3.42x | -6.58x | -16.28x | -3.31x | 2.52x | 1.40x | 1.05x | 1.10x | 1.11x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying CHE stock.
Chemed Corporation (CHE) generated $388.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Chemed Corporation (CHE) generated $325.5M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Chemed Corporation (CHE) spent $62.8M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Chemed Corporation (CHE) returned $31.7M to shareholders via cash dividends and spent $431.5M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Buybacks outpacing internal cash generation
Metrics are mathematically derived from official filings.
Earnings Convert to Cash, But Timing Unreliable
Over ten quarters, Chemed generated $950.7M in operating cash flow against $707.9M in cumulative net income — a 34% premium suggesting solid earnings quality. However, the OCF-to-NI ratio swung from 2.64 to 0.46, indicating significant quarter-to-quarter conversion unpredictability that complicates forward cash flow forecasting.
The cumulative premium is partially explained by substantial non-cash D&A charges totaling approximately $164M across the period, but the wide quarterly dispersion — particularly the 0.46 ratio in Q1 2025 and 0.79 in Q3 2026 — suggests working capital timing and possibly Medicare receivable fluctuations are creating significant noise. Q3 2026's ratio of 0.79 was the second-lowest in the ten-quarter series and represented a sharp deterioration from the 1.30 recorded in the same quarter a year prior, which may indicate deteriorating collection dynamics or a growing accrual component in reported earnings. Investors should track whether the recent conversion weakness reflects a temporary timing artifact or signals a structural shift in the earnings-to-cash relationship.
Free Cash Flow Margins Sharply Compress
Chemed's free cash flow margin has declined from 18.3% in Q4 2025 to just 5.5% in Q3 2026 — the lowest reading since Q1 2025 — reflecting both a $26.8M year-over-year decline in operating cash flow and an $18.7M peak capex quarter, per the company's reported quarterly figures.
This compression is occurring even as net income remains relatively stable at $66–77M per quarter, suggesting the deterioration is driven by working capital drag and rising capital expenditure rather than an underlying operational deterioration. The sequential pattern from 18.3% to 10.8% to 10.3% to 5.5% across the last four quarters is concerning and departs sharply from the 2024Q4 peak of 23.8%. If this trajectory persists, the company's capacity to fund its aggressive buyback program from internal cash generation will be materially constrained, forcing a greater reliance on balance sheet drawdowns.
Working Capital Swings Dominate FCF Volatility
Quarterly working capital changes have swung from +$57.6M in Q2 2025 to -$52.6M in Q1 2025 — a range exceeding $110M that dwarfs underlying operating cash generation. As disclosed in Chemed's cash flow statements, these movements appear to be the single largest driver of free cash flow unpredictability across periods.
This pattern is consistent with the Medicare reimbursement and Cap reserve dynamics central to Chemed's accounting, where the timing of government payments and management-estimated reserve adjustments can create large non-operational cash swings that are difficult to forecast. Roto-Rooter's insurance billing cycle for water restoration work likely compounds the volatility, as service delivery and final cash collection may lag materially. The Q3 2026 working capital contribution of +$6.8M provided only marginal offset to the decline in operating cash flow, suggesting the recent FCF compression is not purely a working capital timing artifact and warrants closer examination of the underlying cash bridge.
Buybacks Have Outpaced Cash Generation
Over trailing ten quarters, Chemed deployed approximately $1.10B in share repurchases and $78M in dividends — totaling roughly $1.18B against $950.7M in cumulative operating cash flow, per Chemed's financial statements, suggesting internal cash generation alone has not fully funded the buyback pace and balance sheet reserves appear to supplement distributions.
The buyback cadence is highly irregular, swinging from $33.2M in Q1 2025 to $209.3M in Q4 2024, indicating opportunistic rather than programmatic repurchase execution tied to market conditions rather than cash availability. The Q1 2026 buyback of $190M coincided with the sharp FCF trough of $71.1M and a poor OCF/NI ratio of 0.46, suggesting management prioritized returning capital even during a weak cash generation quarter. With a fortress-level balance sheet and minimal leverage as noted in prior analysis, this drawdown is sustainable near-term, but the declining FCF trajectory across recent quarters suggests the buyback pace may need to moderate or become more opportunistic.
Stock Compensation Noise Masks Cash Reality
Chemed's stock-based compensation has exhibited extraordinary volatility, swinging from -$15.2M in Q3 2025 to $23.5M in Q4 2025 — a $38.7M range that materially distorts both reported earnings and the reconciling bridge between net income and operating cash flow, per recent SEC filings. This accounting noise warrants careful adjustment.
The negative SBC figure in Q3 2025 suggests reversal of prior expense recognition, potentially related to forfeitures or performance-based award adjustments, which would artificially depress OCF relative to NI in that period and make the 1.30 ratio misleading as a measure of operational cash quality. This accounting noise makes it difficult to isolate the true operational cash generation underlying the headline conversion ratios, and any forward cash flow model should apply normalized SBC assumptions. Additionally, the Medicare Cap reserve — a management-estimated liability — represents a judgment-laden adjustment that may introduce further non-cash volatility, and given the structural reimbursement ceiling facing the VITAS segment identified in prior analysis, the adequacy of this reserve warrants ongoing scrutiny.